In theory, because HER2 tracers inherently only give information about surface expression of receptors, a decline in tracer uptake on serial scans would not necessarily indicate response to treatment; such a decline could just as easily mean that the tumor has mutated and lost HER2 expression due to tumor heterogeneity. This evidence concerns the gene ERBB2 and neoplasm.